

# Around the world of U.S. healthcare in 360 words or less

Center for Healthcare Regulatory Insight

#### March 12, 2021 | Issue 163

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

Subscribe here 🏑

#### Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized <u>COVID-19 news for the week in this special supplement</u>.

0



Healthcare regulatory news

CMMI delayed <u>the Kidney Care Choices Model</u> until 2022, and postponed the <u>seriously ill population component of Primary Care First</u> pending review. HHS extended the <u>comment period on a HIPAA modification rule</u>, proposed further <u>delaying the effective date</u> of a rule requiring FQHCs to pass along to patients 340B discounts on insulin and epinephrine, and is <u>seeking comment on standards</u> for collecting social determinants of health data in EHR systems.

A DHS final rule <u>vacates the Trump Administration public charge rule</u>; earlier in the week, the <u>Supreme Court (SCOTUS) dismissed three cases</u> <u>challenging</u> the rule at the request of the Biden Administration, while 11 <u>Republican-led states motioned to intervene</u> in <u>defense of the policy</u>.

Health and public interest groups <u>sued to stop</u> a Trump Administration <u>rule</u> requiring review of all HHS rules every 10 years.

0



#### Healthcare law and policy news

Congress passed and <u>President Biden signed</u> the \$1.9T <u>American Rescue</u> <u>Plan Act</u> into law... the House will vote next week on <u>legislation extending</u> the pause of 2% <u>Medicare sequester</u> cuts.

Six former FDA Commissioners <u>urged President Biden to name a</u> <u>permanent</u> agency Commissioner... Senate HELP Committee <u>will vote</u> <u>March 17</u> on advancing nominations for Vivek Murthy (Surgeon General) and Rachel Levine (Assistant Secretary for Health).

SCOTUS dismissed <u>arguments on Medicaid work requirements</u> at the Biden Administration's request.

A federal district court <u>vacated four Trump Administration policies</u> related to <u>network adequacy, standardized options, income verification, and MLR</u> in the 2019 ACA exchange rule... A California court <u>preliminarily approved</u> a \$575M antitrust settlement involving Sutter Health; a separate <u>district court</u> <u>dismissed</u> some antitrust <u>claims against Sutter while others proceed to</u> <u>trial</u>... Ohio <u>sued Centene over allegedly obscuring drugs costs</u> and overcharging the Medicaid program.

Takeda <u>will acquire Maverick Therapeutics</u> (\$525M)... CVC Capital Partners <u>hopes to acquire Cooper</u>... PatientPoint and Outcome Health <u>merged</u>... OSF HealthCare <u>plans to acquire a majority stake</u> in Kindred Hospital Peoria.

Athenahealth <u>launched a telehealth insights dashboard</u> to benchmark provider telehealth adoption... Cigna plans to <u>double its individual and</u> <u>family plan membership</u> by 2025.

CDC data indicate the <u>US death rate increased 15% last year</u>, driven by COVID-19... USPSTF <u>recommended annual lung cancer screening</u> for people <u>as young as 50</u> with shorter smoking histories.

0

Questions or comments, please send to <u>us-</u> hcinsight@kpmg.com.

### Succeeding in the new reality

Visit the COVID-19 resource center for KPMG analysis, insights, and perspectives.



kpmq.com/socialmedia



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



## COVID-19 News Supplement

#### **Center for Healthcare Regulatory Insight**



#### COVID-19 by the Numbers

There are now over 29.2 million confirmed COVID-19 cases in the US, with a <u>death toll over 530,000</u>... The United States is <u>averaging fewer than 50,000 COVID-19 new confirmed cases per day</u> for the first time in over five months as the national <u>testing rate continues to decline</u>... HHS and the Defense Department estimate that the United States is <u>running 6 million COVID-19 tests each day</u> and that capacity exists to conduct an additional 150 million tests per month if the existing supply was supplemented.

98.2 million COVID-19 <u>vaccine doses have been administered</u> in the US (2.23M/day over the last week)... 69% of Americans 75 and older and 60% of Americans 65 and older have received at least one dose of a COVID-19 vaccine.

CDC reported that about 78% of people who were hospitalized, placed on a ventilator, or died from COVID-19 were overweight (28.3%) or obese (50.8%)... The HHS Inspector General is examining how CDC can improve the accuracy of its data on the impact of COVID-19 based on race and ethnicity.

#### Executive and Administrative Action

In a primetime address, President Biden said he will <u>direct all states, tribes and territories to open up</u> <u>vaccine eligibility to all adults</u> by no later than May 1 and said the country could return to near-normal by July 4<sup>th</sup> if people continue to wear masks, take precautions, and get vaccinated... HHS guidance <u>permits midwives, paramedics, and dentists to now administer COVID-19 vaccines</u> without being held liable for possible harms.

CDC <u>guidelines state that individuals</u> fully vaccinated against COVID-19 can gather indoors and unmasked with other fully vaccinated individuals, visit unvaccinated people from a single household who are at low risk of serious disease, and refrain from quarantine and testing following a known exposure if asymptomatic... CMS, in coordination with CDC, <u>updated guidance</u> to <u>expand nursing home</u> visitation options.

The Biden Administration will <u>release temporary safety rules next week</u> to protect workers from COVID-19 exposure on the job, including requiring employers to follow CDC and OSHA guidelines.

The Administration will <u>offer \$250 million in federal grants</u> to community organizations working to combat inequities in COVID-19 response.

#### Healthcare Regulatory News

FDA granted emergency use authorization for <u>Cue's molecular COVID-19 test for home and over the</u> <u>counter</u> (without a prescription) use and <u>Abbot's test that detects and differentiates</u> between COVID-19, influenza A, influenza B, and respiratory syncytial virus.

#### Healthcare Law, Business, and Policy News

<u>PhRMA</u> and <u>BIO</u> separately <u>urged President Biden to not support a global waiver of patent and</u> <u>intellectual property protections</u> for COVID-19 vaccines and other products.

Some large employers are <u>receiving permission from public health officials to vaccinate</u> their employees at work.

A <u>Nature study examined</u> predictors of "long COVID," including fatigue, headache, shortness of breath, fever, cough, hoarse voice, and muscle pain in the first week of infection... KFF reported that 54% of individuals who <u>got their first COVID-19 vaccine dose through a community health center</u> were people of color.

An Axios/Ipsos poll found that only <u>7% of Americans plan to stop wearing a face mask</u> in public after they are vaccinated and roughly one in five Americans don't know when they will return to normal, pre-COVID-19 levels of activity outside their household.

#### Surveillance, Testing, and Treatment

The Biden Administration will <u>distribute 18.5 million COVID-19 vaccine doses</u> this week, down 2.5 million from last week... The Administration plans to <u>secure another 100 million doses</u> of Johnson & Johnson's COVID-19 vaccine.

The Biden Administration also <u>opened two new FEMA-supported high volume vaccination sites</u> in HHS announced <u>an additional 700 HRSA-supported health centers</u> would join the Health Center COVID-19 Vaccine Program... Atlanta and Cleveland and <u>announced a \$650 million expansion of testing</u> in K-8 schools and congregate settings using testing hubs... NIH Director Francis Collins hopes to keep the <u>Rapid Acceleration of Diagnostics (RADx<sup>SM</sup>) initiative</u>, developed to speed innovation in COVID-19 testing technologies, <u>going after the pandemic ends</u>.

Alaska made COVID-19 vaccines available for all residents and workers over 16 years of age.

A <u>New England Journal of Medicine study found</u> that the Pfizer-BioNTech COVID-19 vaccine showed "roughly equivalent" <u>levels of neutralizing activity against COVID-19 variants</u> first detected in the UK and Brazil, and a "robust but lower" effect against the South African variant... Real world evidence suggests that Pfizer-BioNTech's vaccine is <u>at least 97% effective in preventing symptomatic COVID-19 cases</u> and 94% effective against asymptomatic infection... BioNTech expects capacity to <u>make 3 billion doses</u> of COVID-19 vaccines in 2022.

Novavax reported that its <u>COVID-19 vaccine is 96.4% effective against the original strain of COVID-19</u> and 86.3% effective against the strain first identified in the US and prevents severe illness entirely.

Moderna, Novavax, and University of Oxford are <u>developing multivalent COVID-19 vaccines</u> that could protect against both existing and future strains of the virus... Moderna reported that the <u>first study</u>

volunteers have received modified COVID-19 vaccines developed to target emerging variants... Baxter will <u>support "fill/finish manufacturing" of Moderna's</u> COVID-19 vaccine.

AstraZeneca has <u>begun stockpiling its COVID-19 vaccine</u> for use in the United States, with 30 million doses ready for distribution once granted authorization by the FDA.

Sanofi and Translate Bio started a phase 1/2 trial of their COVID-19 vaccine based on mRNA technology.

Duke researchers are undertaking a <u>real-world study of healthcare workers</u> on the <u>long-term effects of</u> <u>different COVID-19 vaccines</u>... Russian intelligence agencies are <u>attempting to undermine public trust</u> in COVID-19 vaccines from Pfizer and other manufacturers.

Eli Lilly reported that its combination monoclonal antibody COVID-19 therapy <u>reduced the risk of</u> <u>hospitalization and death by 87%</u> in a trial of high-risk patients... Vir Biotechnology and GlaxoSmithKline reported that their monoclonal antibody therapy <u>reduced hospitalizations or death by 85%</u>, and that they plan to seek emergency use authorization for the treatment.

An experimental COVID-19 drug from Merck and Ridgeback Biotherapeutics <u>significantly reduced</u> <u>infectious virus</u> among COVID-19 patients after five days of treatment in a preliminary trial.